Valeant Pharma to Restate Earnings After Board Review

The transcript discusses Valiant's financial investigation, revealing issues with revenue recording and a $58 million adjustment. It highlights the scrutiny from the healthcare system and market reactions, including Deutsche's downgrade of Express Scripts. Analysts have mixed opinions, with some optimistic and others, like David Maris, skeptical. The stock has seen significant fluctuations, and the future outlook remains uncertain amid ongoing challenges.

What was the primary reason for Valeant's $58 million financial adjustment?

• Incorrect revenue recording

• Increased production costs

• New product launch

• Acquisition of a new company

What is the main concern of the healthcare system regarding Valeant?

• Their product pricing

• Their marketing strategies

• Their research and development

• Their operational transparency

What percentage of analysts still favored Valeant despite its issues?

• 30%

• 60%

• 90%

• 50%

What was David Maris's price target for Valeant's stock?

• $200

• $80

• $66

• $150

How did the market react to David Maris's report on Valeant?

• Stock price remained stable

• Stock price decreased by 10% on two consecutive days

• Stock price increased by 10%

• Stock price increased by 5%